James Kihara Sells 1,095 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Stock

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) insider James Kihara sold 1,095 shares of the company’s stock in a transaction that occurred on Wednesday, March 26th. The stock was sold at an average price of $17.05, for a total transaction of $18,669.75. Following the transaction, the insider now directly owns 21,275 shares of the company’s stock, valued at $362,738.75. This trade represents a 4.89 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

James Kihara also recently made the following trade(s):

• On Monday, February 24th, James Kihara sold 475 shares of ACADIA Pharmaceuticals stock. The shares were sold at an average price of $19.96, for a total transaction of $9,481.00.

ACADIA Pharmaceuticals Price Performance

ACAD traded down $0.08 during trading on Wednesday, hitting $17.03. The company had a trading volume of 902,668 shares, compared to its average volume of 1,762,028. ACADIA Pharmaceuticals Inc. has a 1-year low of $14.15 and a 1-year high of $20.68. The company has a market cap of $2.84 billion, a PE ratio of 21.83 and a beta of 0.43. The business has a 50-day moving average of $18.35 and a 200-day moving average of $17.02.

Hedge Funds Weigh In On ACADIA Pharmaceuticals

Large investors have recently modified their holdings of the stock. SG Americas Securities LLC raised its stake in ACADIA Pharmaceuticals by 380.3% during the fourth quarter. SG Americas Securities LLC now owns 2,483,731 shares of the biopharmaceutical company’s stock valued at $45,576,000 after buying an additional 1,966,607 shares in the last quarter. Barclays PLC raised its position in shares of ACADIA Pharmaceuticals by 126.2% during the 3rd quarter. Barclays PLC now owns 277,565 shares of the biopharmaceutical company’s stock valued at $4,269,000 after acquiring an additional 154,854 shares in the last quarter. Burney Co. acquired a new stake in shares of ACADIA Pharmaceuticals during the 4th quarter valued at approximately $6,953,000. Proficio Capital Partners LLC bought a new position in ACADIA Pharmaceuticals during the fourth quarter worth $272,000. Finally, BNP Paribas Financial Markets boosted its holdings in ACADIA Pharmaceuticals by 259.0% in the third quarter. BNP Paribas Financial Markets now owns 223,618 shares of the biopharmaceutical company’s stock worth $3,439,000 after purchasing an additional 161,331 shares during the period. Institutional investors own 96.71% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on ACAD. Morgan Stanley reiterated an “equal weight” rating and issued a $20.00 target price on shares of ACADIA Pharmaceuticals in a report on Friday, March 7th. StockNews.com upgraded ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, March 8th. Cantor Fitzgerald reissued an “overweight” rating and set a $28.00 target price on shares of ACADIA Pharmaceuticals in a research report on Thursday, February 27th. Guggenheim cut shares of ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price target for the company from $23.00 to $20.00 in a research report on Friday, January 3rd. Finally, HC Wainwright reissued a “buy” rating and issued a $27.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Thursday, February 27th. Eight equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $23.93.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.